



Investment Process

We seek long-term investments in high-quality businesses exposed to structural growth themes that can be acquired at sensible valuations in a contrarian fashion and are led by excellent management teams.

Investing with Tailwinds

We identify structural themes at the intersection of growth and change with the objective of investing in companies having meaningful exposure to these trends. Themes can be identified from both bottom-up and top-down perspectives.

High-Quality Businesses

We seek future leaders with attractive growth characteristics that we can own for the long term. Our fundamental analysis focuses on those companies exhibiting unique and defensible business models, high barriers to entry, proven management teams, favorable positions within their industry value chains and high or improving returns on capital. In short, we look to invest in small companies that have potential to become large.

A Contrarian Approach to Valuation

We seek to invest in high-quality businesses in a contrarian fashion. Mismatches between stock price and long-term business value are created by market dislocations, temporary slowdowns in individual businesses or misperceptions in the investment community. We also examine business transformation brought about by management change or restructuring.

Manage Unique Risks of International Small- and Mid-Cap Equities

International small- and mid-cap equities are exposed to unique investment risks that require managing. We define risk as permanent loss of capital, not share price volatility. We manage this risk by having a long-term ownership focus, understanding the direct and indirect security risks for each business, constructing the portfolio on a well-diversified basis and sizing positions according to individual risk characteristics.

Team Overview

Our team is intellectually curious about the world and how it is changing. Each team member is passionate about small company investing and discovering businesses with meaningful and open-ended growth opportunities.

Portfolio Management



Rezo Kanovich
Portfolio Manager

Investment Results (% USD)

| As of 30 June 2021 | Average Annual Total Returns | | | | | | |
|---|------------------------------|-------------|--------------|------|------|-------|------------------------|
| | QTD | YTD | 1 Yr | 3 Yr | 5 Yr | 10 Yr | Inception ¹ |
| Composite — Gross | 7.63 | 6.51 | 43.20 | — | — | — | 31.83 |
| Composite — Net | 7.37 | 5.98 | 41.80 | — | — | — | 30.50 |
| MSCI All Country World ex USA SMID Index | 6.05 | 10.52 | 41.80 | — | — | — | 18.08 |
| MSCI All Country World ex USA Small Cap Index | 6.35 | 12.24 | 47.04 | — | — | — | 19.77 |

Annual Returns (% USD) 12 months ended 30 June

| | 2017 | 2018 | 2019 | 2020 | 2021 |
|--------------------------|------|------|------|--------------|--------------|
| Composite — Gross | — | — | — | 12.29 | 43.20 |

Source: Artisan Partners/MSCI. Returns for periods less than one year are not annualized. ¹Composite inception: 1 January 2019.

Past performance does not guarantee and is not a reliable indicator of future results. Current performance may be lower or higher than the performance shown. Composite performance has been presented in both gross and net of investment management fees.

Investment Risks: Investments will rise and fall with market fluctuations and investor capital is at risk. Investors investing in strategies denominated in non-local currency should be aware of the risk of currency exchange fluctuations that may cause a loss of principal. These risks, among others, are further described near the back of this document, which should be read in conjunction with this material.



Investing Environment

Global equities continued their YTD rise in Q2, with all sectors participating in the market's upward trajectory. The second quarter was also punctuated by brief periods of volatility, as a staggered economic reopening and concerns about rising inflation in parts of Europe and the US impacted investor sentiment. Strength was broad based among small- and mid-cap stocks with health care, energy and industrials leading the way.

Over the first half of the year, investors largely debated style leadership and the sustainability of rallies in asset classes such as commodities and cryptocurrencies. We, however, remained focused on long-term ownership in high-quality businesses exposed to structural tailwinds. Well-run, innovative companies with meaningful competitive advantages, structurally high returns on capital, and strong balance sheets provide resilience amid market gyrations, and, in our view, present the best chance to compound long-term returns. We also continued to look for opportunities to take advantage of market volatility and make investments where we believe we can double our shareholders' money over five years.

One macroeconomic topic of intense interest this year has been inflation. While in the short-term investors may attempt to hedge inflation with speculation on commodities, we believe the best way to combat inflation over the long term is to invest in businesses that command sustainable pricing power and have sustainable volume growth. The ingredients of pricing power include customer intimacy, high value-added bottleneck positioning in an industry value chain, and the ability to continuously create value for one's customers via innovation or benefits of scale. We have highlighted these characteristics in prior letters as hallmarks of companies we look to invest in across industries, ranging from technology to health care to industrials to consumer. We'll discuss how advances in artificial intelligence (AI) create meaningful pricing power for these businesses, and why we believe they are vastly superior to undifferentiated commodities, where long-term values are difficult to pinpoint.

Another macroeconomic topic of investor interest has been the potential rise in long-term interest rates in response to rising inflation. We believe there are two key points to consider in this scenario. The first point is the importance of investing in structurally high return on capital businesses since the value of a business is driven by the spread between the cost of capital and return on capital. For example, if the cost of capital rises from 2% to 3%, a low return on capital business is massively disadvantaged and would have most of its economic value add eliminated. In comparison, a high return on capital business would be much less impacted. The second point is the importance of low debt levels. Our companies typically carry little to no debt, and hence, increases in the cost of capital would have negligible effects on their interest costs or their bottom lines.

While the market may continue to debate benefits of growth vs. value investing, we continue to focus on the fundamental progress of our portfolio companies and the true drivers of value creation over the

long term. We think the technology sector provides a good illustration of the market's short-termism. Thus far in 2021, share prices of certain technology companies have been highly volatile over shorter timeframes, with a selloff in Q1 and a rally in Q2. Fundamentally, little to nothing changed. The momentum trade is often widespread in tech; however, our approach continues to be nuanced, highly focused on sustainability and price disciplined. Regardless of the prevailing risk on/risk off environment, there is tremendous progress in technology with digitization permeating every industry, cloud computing proliferating and AI coming of age. Technology continuously creates value for its customers, and we believe that if one creates disproportional value, then one will be able to exercise pricing power.

It is becoming evident that AI and big data are being rapidly adopted across various industries. For example, just a few years ago, virtually no health care companies incorporated AI. Now, ViewRay and Elekta, two portfolio companies discussed further in the next section, are using AI in their MRI cancer radiation machines to optimize radiation, avoid hitting healthy tissue and shorten therapy cycles. That's a huge value for customers and patients for which they can price. Alcon and Carl Zeiss, portfolio companies discussed in prior letters, are implementing AI analysis of retinal images to enable remote diagnosis of ophthalmological diseases. Another example is Ambu, also discussed in the next section, which is looking to incorporate AI-enabled digital pathology tools into its disposable endoscopes.

In enterprise software, we can also highlight several examples where AI is creating significant value for its customers. For example, NICE Systems, which we have discussed in prior letters, is leading the commercialization of AI in its customer interaction software and financial fraud and compliance platform, Actimize. AI allows the company to meaningfully broaden the number of seats within the enterprise and to cross-sell high value analytics and management tools. We've added meaningfully to our position on recent share price weakness. The next two examples are benefiting from AI's growing importance in industry-specific software, which is creating opportunities for small companies that specialize to succeed and command pricing power. Model N is using AI to optimize customer contracting software in high value-added industries, such as technology and pharmaceuticals, where complexity is extremely high. Creating optimal discount structures results in very high savings for Model N's customers and the end consumers. Altus, which caters to the global commercial real estate market, is using AI to aggregate and analyze vast amounts of real estate transaction data for its customers, which provides high value market intelligence for its customers.

To summarize, we believe that our investors will be in a far better position over the long term by investing in companies that respect long-term customer relationships and exercise pricing power in a disciplined fashion. Compounding high returns on capital in such businesses, in our view, is vastly superior to trying to forecast copper

prices. Hence, we remain highly priced disciplined and continue to focus on structural trends and company fundamentals.

Performance Discussion

Our portfolio outperformed the MSCI ACWI ex USA SMID Index in Q2. Our health care, industrials and materials holdings were the largest contributors to relative returns, and technology positions added strongly to absolute returns.

The top individual contributors in Q2 were Kornit Digital, Carenet and ViewRay. Kornit's revolutionary technology allows for direct printing on garments and is enabling the apparel industry's structural shift to automation, instant fashion and increased mass customization. The COVID-19 pandemic served to reinforce the need for better inventory management and desire to bring production closer to the customer. Moreover, it's important to note that the textile industry is second only to the petroleum industry in terms of its environmental footprint, and Kornit has a leading role in helping to reduce it. Kornit's premier customer relationships, which it continues to expand, and the long tail of high-margin proprietary ink consumables and services, support sustainable cash flows.

Carenet offers a digital platform for pharmaceutical sales and highly curated educational content for physicians in Japan. Founded in 1996, the company is likely most comparable to WebMD in the US. We recently added Carenet to the portfolio after conducting a thorough global industry review of health care and digitization trends and concluding that health care will digitize meaningfully, and the COVID-19 pandemic served to accelerate this trend. We believe that Carenet will leverage its high-quality industry position to build out several additional high value-added services for pharmaceutical clients and for other areas of health care that are rapidly digitizing.

ViewRay's MRIdian MR-LINAC system is a leading cancer radiation therapy platform, combining AI-enabled MRI visualization with cancer radiation therapy. As mentioned in the prior section, this approach spares healthy tissue and shortens therapy cycles by exclusively targeting cancer, and we believe it is the next-generation modality for cancer radiation therapy. We hold two leading companies with this technology, ViewRay in the US and its Swedish competitor Elekta. Despite COVID-19 headwinds, this technology is rapidly gaining traction worldwide.

The largest detractors this quarter were Trainline, Ambu and HENNGE. Trainline is a UK-based online booking provider for rail travel. Reduced travel during the pandemic hampered revenues over the past year. Additionally, the UK government's proposed plan to consolidate the country's rail industry has placed pressure on the stock. Despite these recent headwinds, company management is preparing for the gradual return to travel by concentrating on customer-focused innovation and global expansion. This includes a shift to digital sales and offering flexi-tickets for hybrid commuters. The rail industry is growing, and we believe Trainline is primed to capture market share and should emerge from this period stronger.

Ambu is a medical device company that pioneered single-use, disposable endoscopes, replacing equipment that requires sterilization after each use. The company's initial markets in which the products are used include bronchoscopy and cystoscopy (bladder and kidney). We believe that utilization of single-use endoscopes will spread to much larger markets, such as gastroscopy, colonoscopy and duodenoscopy, and that Ambu has meaningful opportunity to implement AI-enabled digital pathology into its tools. In the shorter term, the stock has been weak due to delays in duodenoscope development. However, our conviction in the company over the long term remains in place.

HENNGE has a single sign-on technology that allows companies to manage decentralized workforces. The stock performed extraordinarily well during the pandemic and, in our view, became excessively valued. Remaining committed to our contrarian approach to valuation, we trimmed the position. More recently, we added to it as the stock price appears reasonably valued once again.

Positioning

Given the richness of our investment universe and the amount of change taking place in world, there are always promising investment opportunities. As a portfolio that targets a five-year holding period for its securities—and invests in high-quality companies backed by structural tailwinds—we remain focused on the forces shaping the next decade. The portfolio activity discussed in this letter is not an exhaustive report but a representative sampling of the exciting businesses we continue to find.

During Q2, we took advantage of market volatility and made a number of new investments, including an intellectual processing company that licenses high value-added technologies, a Japan-based cloud native software company and a UK-based edge computing company.

We also exited several positions, including STAAR Surgical, Hypoport, Atos and Morinaga & Co. Our sensitivity to price led us to exit the first two companies. We sold Atos in favor of other opportunities in which we have higher conviction. Lastly, we exited Morinaga & Co on capital allocation concerns.

We thank you for your trust and confidence and look forward to updating you on these and other opportunities in future letters.

ARTISAN CANVAS

Timely insights and updates from our investment teams and firm leadership

Visit www.artisancanvas.com

For more information: Visit www.artisanpartners.com

Investment Risks: International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period. These risks, among others, are further described in Artisan Partners Form ADV, which is available upon request.

Unless otherwise indicated, the Artisan Strategy characteristics relate to that of an investment composite or a representative account managed within a composite. It is intended to provide a general illustration of the investment strategy and considerations used by Artisan Partners in managing that strategy. Individual accounts may differ, at times significantly, from the reference data shown due to varying account restrictions, fees and expenses, and since-inception time periods, among others. Where applicable, this information is supplemental to, and not to be construed with, a current or prospective client's investment account information. References to individual security performance relate to a representative account in the composite. Individual holding periods may differ.

Securities referenced may not be representative of all portfolio holdings. Securities of the same issuer are aggregated to determine a holding's portfolio weight. Portfolio statistics calculations exclude outlier data and certain securities which lack applicable attributes, such as private securities. Artisan Partners may substitute information from a related security if unavailable for a particular security. This material is as of the date indicated and is subject to change without notice. Totals may not sum due to rounding.

Attribution is used to evaluate the investment management decisions which affected the portfolio's performance when compared to a benchmark index. Attribution is not exact, but should be considered an approximation of the relative contribution of each of the factors considered.

Net-of-fees composite returns were calculated using the highest model investment advisory fees applicable to portfolios within the composite. Fees may be higher for certain pooled vehicles and the composite may include accounts with performance-based fees. All performance results are net of commissions and transaction costs, and have been presented gross and net of investment advisory fees. Dividend income is recorded net of foreign withholding taxes on ex-dividend date or as soon after the ex-dividend date as the information becomes available to Artisan Partners. Interest income is recorded on the accrual basis. Performance results for the Index include reinvested dividends and are presented net of foreign withholding taxes but, unlike the portfolio's returns, do not reflect the payment of sales commissions or other expenses incurred in the purchase or sale of the securities included in the indices.

MSCI All Country World ex USA SMID Index measures the performance of small- and mid-cap companies in developed and emerging markets excluding the US. MSCI All Country World Small Cap Index measures the performance of small-cap companies in developed and emerging markets. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used to create indices or financial products. This report is not approved or produced by MSCI.

The Global Industry Classification Standard (GICS[®]) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

This summary represents the views of the portfolio manager as of 30 Jun 2021. Those views and portfolio holdings are subject to change and Artisan Partners disclaims any obligation to advise investors of such changes. The discussion of portfolio holdings does not constitute a recommendation of any individual security. For a complete list of holdings by contribution to the strategy, refer to the Contributors to Return chart.

Return on Capital (ROC) is a measure of how effectively a company uses the money (borrowed or owned) invested in its operations.

This material is provided for informational purposes without regard to your particular investment needs. This material shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein. In no event shall Artisan Partners have any liability for direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) losses or any other damages resulting from the use of this material.

Artisan Partners Limited Partnership (APLP) is an investment adviser registered with the U.S. Securities and Exchange Commission (SEC). Artisan Partners UK LLP (APUK) is authorized and regulated by the Financial Conduct Authority and is a registered investment adviser with the SEC. APEL Financial Distribution Services Limited (AP Europe) is authorized and regulated by the Central Bank of Ireland. APLP, APUK and AP Europe are collectively, with their parent company and affiliates, referred to as Artisan Partners herein. Artisan Partners is not registered, authorised or eligible for an exemption from registration in all jurisdictions. Therefore, services described herein may not be available in certain jurisdictions. This material does not constitute an offer or solicitation where such actions are not authorised or lawful, and in some cases may only be provided at the initiative of the prospect. Further limitations on the availability of products or services described herein may be imposed.

This material is only intended for investors which meet qualifications as institutional investors as defined in the applicable jurisdiction where this material is received, which includes only *Professional Clients* or *Eligible Counterparties* as defined by the Markets in Financial Instruments Directive (MiFID) where this material is issued by APUK or AP Europe. This material is not for use by retail investors and may not be reproduced or distributed without Artisan Partners' permission.

In the United Kingdom, issued by APUK, 25 St. James's St., Floor 3, London SW1A 1HA, registered in England and Wales (LLP No. OC351201). Registered office: Reading Bridge House, Floor 4, George St., Reading, Berkshire RG1 8LS. In Ireland, issued by AP Europe, Fitzwilliam Hall, Fitzwilliam Pl, Ste. 202, Dublin 2, D02 T292. Registered office: 70 Sir John Rogerson's Quay, Dublin 2, D02 R296 (Company No. 637966).

Australia: This material is directed at wholesale clients only and is not intended for, or to be relied upon by, private individuals or retail investors. Artisan Partners Australia Pty Ltd is a representative of APLP (ARBN 153 777 292) and APUK (ARBN 603 522 649). APLP and APUK are respectively regulated under US and UK laws which differ from Australian laws and are exempt from the requirement to hold an Australian financial services license under the Australian Corporations Act 2001 in respect to financial services provided in Australia.

Canada: This material is distributed in Canada by APLP and/or Artisan Partners Distributors LLC, which conduct activities in Canada under exemptions from the dealer, portfolio manager and investment fund manager registration requirements of applicable Canadian securities laws. This material does not constitute an offer of services in circumstances where such exemptions are not available. APLP advisory services are available only to investors that qualify as "permitted clients" under applicable Canadian securities laws.

© 2021 Artisan Partners. All rights reserved.

For Institutional Investors – Not for Onward Distribution



Artisan Non-U.S. Small-Mid Growth Strategy

Quarterly Contribution to Return (% USD)

As of 30 June 2021

| Top Contributors | Average Weight | Contribution to Return | Ending Weight |
|-----------------------------------|----------------|------------------------|---------------|
| Kornit Digital Ltd | 2.24 | 0.59 | 2.64 |
| Carenet Inc | 0.80 | 0.46 | 1.03 |
| ViewRay Inc | 0.96 | 0.42 | 1.24 |
| Nice Ltd | 2.86 | 0.38 | 3.29 |
| ConvaTec Group PLC | 1.69 | 0.37 | 1.78 |
| Toshiba Corp | 1.22 | 0.33 | 1.24 |
| Jeol Ltd | 0.90 | 0.33 | 0.93 |
| AIXTRON SE | 1.65 | 0.32 | 1.58 |
| I-Mab | 0.53 | 0.30 | 0.42 |
| SG Holdings Co Ltd | 1.94 | 0.29 | 2.24 |
| BioCryst Pharmaceuticals Inc | 0.54 | 0.26 | 0.54 |
| Petrobras Distribuidora SA | 0.64 | 0.24 | 0.71 |
| Genmab A/S | 1.06 | 0.23 | 1.11 |
| Roland Corp | 0.68 | 0.22 | 0.69 |
| DSV PANALPINA A/S | 1.14 | 0.22 | 0.99 |
| Radware Ltd | 1.27 | 0.21 | 1.37 |
| Alkermes PLC | 0.75 | 0.20 | 0.78 |
| St James's Place PLC | 1.04 | 0.19 | 1.07 |
| Howden Joinery Group PLC | 1.16 | 0.16 | 1.16 |
| Lectra | 1.05 | 0.16 | 1.05 |
| IMCD NV | 1.06 | 0.16 | 1.07 |
| Afya Ltd | 0.50 | 0.16 | 0.54 |
| Oxford Biomedica PLC | 0.47 | 0.15 | 0.53 |
| Comet Holding AG | 0.82 | 0.15 | 0.89 |
| Lantheus Holdings Inc | 0.48 | 0.14 | 0.64 |
| Davide Campari-Milano NV | 0.73 | 0.14 | 0.76 |
| Almirall SA | 0.89 | 0.14 | 0.92 |
| Legend Biotech Corp | 0.35 | 0.13 | 0.45 |
| Agilysys Inc | 0.68 | 0.13 | 0.83 |
| Metso Outotec Oyj | 2.04 | 0.13 | 1.93 |
| CAE Inc | 1.54 | 0.12 | 1.55 |
| Money Forward Inc | 0.31 | 0.12 | 0.58 |
| ALK-Abello A/S | 0.53 | 0.12 | 0.57 |
| Siegfried Holding AG | 0.90 | 0.12 | 0.92 |
| Symrise AG | 0.74 | 0.11 | 0.76 |
| JD Sports Fashion PLC | 0.85 | 0.11 | 0.74 |
| WNS Holdings Ltd | 1.02 | 0.11 | 1.19 |
| Establishment Labs Holdings Inc | 0.31 | 0.11 | 0.35 |
| Koninklijke DSM NV | 0.96 | 0.11 | 0.96 |
| Carlsberg AS | 0.56 | 0.11 | 0.57 |
| Fevertree Drinks PLC | 0.56 | 0.11 | 0.56 |
| STAAR Surgical Co | 0.24 | 0.10 | 0.00 |
| Belimo Holding AG | 0.75 | 0.10 | 0.79 |
| Tecan Group AG | 0.79 | 0.10 | 0.79 |
| Fortnox AB | 0.98 | 0.09 | 1.01 |
| Elekta AB | 0.71 | 0.09 | 0.51 |
| Kinaxis Inc | 0.68 | 0.09 | 0.80 |
| Carl Zeiss Meditec AG | 0.31 | 0.09 | 0.30 |
| The Descartes Systems Group Inc | 0.69 | 0.09 | 0.74 |
| Britvic PLC | 0.69 | 0.09 | 0.69 |
| YouGov PLC | 0.51 | 0.09 | 0.53 |
| Electrocomponents PLC | 1.58 | 0.08 | 1.52 |
| Burckhardt Compression Holding AG | 0.40 | 0.08 | 0.41 |

Continued on next page.

| Bottom Contributors | Average Weight | Contribution to Return | Ending Weight |
|---------------------------------|----------------|------------------------|---------------|
| Trainline PLC | 0.66 | -0.29 | 0.55 |
| Ambu A/S | 1.07 | -0.22 | 0.88 |
| Henнге KK | 0.42 | -0.21 | 0.19 |
| Intersect ENT Inc | 0.87 | -0.19 | 0.83 |
| HomeServe PLC | 0.69 | -0.16 | 0.61 |
| MorphoSys AG | 1.55 | -0.16 | 1.37 |
| Orchard Therapeutics PLC | 0.40 | -0.15 | 0.27 |
| Oncoceptides AB | 0.36 | -0.15 | 0.31 |
| ASOS PLC | 1.26 | -0.14 | 1.19 |
| Atos SE | 0.41 | -0.13 | 0.00 |
| Raccoon Holdings Inc | 0.91 | -0.13 | 0.71 |
| Cree Inc | 1.42 | -0.12 | 1.36 |
| boohoo Group PLC | 1.48 | -0.12 | 1.51 |
| JET2 PLC | 1.63 | -0.10 | 1.43 |
| IndiaMart InterMesh Ltd | 0.89 | -0.10 | 0.79 |
| MedPeer Inc | 0.19 | -0.08 | 0.00 |
| Global Blood Therapeutics Inc | 0.53 | -0.07 | 0.46 |
| Azbil Corp | 1.52 | -0.07 | 1.64 |
| Insmed Inc | 0.21 | -0.06 | 0.00 |
| Kitanotatsujin Corp | 0.22 | -0.06 | 0.20 |
| SSP Group PLC | 0.34 | -0.05 | 0.29 |
| Madrigal Pharmaceuticals Inc | 0.30 | -0.05 | 0.23 |
| Morinaga & Co Ltd | 0.25 | -0.04 | 0.00 |
| TechMatrix Corp | 0.57 | -0.04 | 0.55 |
| Rohm Co Ltd | 0.77 | -0.04 | 0.71 |
| Baloise Holding AG | 0.96 | -0.04 | 0.87 |
| Vestas Wind Systems A/S | 0.68 | -0.03 | 0.69 |
| Zogenix Inc | 0.28 | -0.03 | 0.25 |
| Altus Group Ltd | 1.05 | -0.03 | 1.00 |
| Rotork PLC | 1.63 | -0.03 | 1.56 |
| Model N Inc | 1.25 | -0.03 | 1.22 |
| Accelaron Pharma Inc | 0.34 | -0.03 | 0.30 |
| Inspire Medical Systems Inc | 0.40 | -0.03 | 0.37 |
| Gaztransport Et Technigaz SA | 0.37 | -0.02 | 0.73 |
| Alphawave IP Group PLC | 0.25 | -0.02 | 0.54 |
| Flexion Therapeutics Inc | 0.31 | -0.02 | 0.29 |
| Protara Therapeutics Inc | 0.02 | -0.02 | 0.00 |
| Ergomed PLC | 0.35 | -0.01 | 0.33 |
| Essa Pharma Inc | 0.02 | -0.01 | 0.09 |
| eSOL Co Ltd | 0.07 | -0.01 | 0.06 |
| Morinaga Milk Industry Co Ltd | 0.55 | -0.01 | 0.54 |
| Max Stock Ltd | 0.29 | -0.01 | 0.29 |
| Ingersoll Rand Inc | 1.03 | -0.01 | 1.00 |
| Sagami Rubber Industries Co Ltd | 0.07 | -0.01 | 0.06 |
| Verastem Inc | 0.02 | -0.00 | 0.08 |
| Compugen Ltd | 0.07 | -0.00 | 0.07 |
| Tel Aviv Stock Exchange Ltd | 0.43 | -0.00 | 0.39 |
| Glaukos Corp | 0.91 | 0.00 | 0.92 |
| Cantargia AB | 0.00 | 0.00 | 0.00 |
| Quotient Ltd | 0.15 | 0.00 | 0.14 |
| Alcon Inc | 1.68 | 0.00 | 1.66 |
| Cash Holdings | 1.32 | 0.00 | 1.26 |
| AAK AB | 0.94 | 0.01 | 0.92 |

Artisan Non-U.S. Small-Mid Growth Strategy

Quarterly Contribution to Return (% USD)

As of 30 June 2021

| Top Contributors (continued) | Average Weight | Contribution to Return | Ending Weight |
|---|----------------|------------------------|---------------|
| Reata Pharmaceuticals Inc | 0.19 | 0.08 | 0.25 |
| Alnylam Pharmaceuticals Inc | 0.39 | 0.08 | 0.44 |
| Hamburger Hafen und Logistik AG | 0.52 | 0.08 | 0.51 |
| Temairazu Inc | 0.33 | 0.07 | 0.34 |
| Fabrinet | 1.01 | 0.07 | 1.07 |
| Revenio Group Oyj | 0.28 | 0.07 | 0.29 |
| Kobe Bussan Co Ltd | 0.45 | 0.07 | 0.46 |
| B&M European Value Retail SA | 0.72 | 0.06 | 0.72 |
| AVEVA Group PLC | 0.77 | 0.06 | 0.65 |
| en Japan Inc | 0.34 | 0.06 | 0.40 |
| Lonza Group AG | 0.24 | 0.06 | 0.00 |
| KION Group AG | 0.58 | 0.05 | 0.58 |
| Notre Dame Intermedica Participacoes SA | 0.31 | 0.05 | 0.38 |
| Ubicom Holdings Inc | 0.29 | 0.05 | 0.41 |
| Argenx SE | 0.41 | 0.04 | 0.43 |
| Vaisala Oyj | 0.35 | 0.04 | 0.31 |
| Ossur HF | 0.59 | 0.04 | 0.58 |
| New Work SE | 0.19 | 0.04 | 0.20 |

| Bottom Contributors (continued) | Average Weight | Contribution to Return | Ending Weight |
|--|----------------|------------------------|---------------|
| SimCorp A/S | 0.38 | 0.01 | 0.36 |
| Hypoport SE | 0.36 | 0.01 | 0.00 |
| Obic Co Ltd | 0.52 | 0.01 | 0.50 |
| Rami Levy Chain Stores Hashikma Marketing 2006 Ltd | 0.24 | 0.01 | 0.24 |
| OBIC Business Consultants Co Ltd | 0.03 | 0.01 | 0.00 |
| MaxCyte Inc | 0.60 | 0.01 | 0.59 |
| Telix Pharmaceuticals Ltd | 0.02 | 0.01 | 0.12 |
| Varex Imaging Corp | 0.11 | 0.02 | 0.17 |
| CKD Corp | 1.28 | 0.02 | 1.21 |
| Myriad Genetics Inc | 0.11 | 0.02 | 0.37 |
| Balfour Beatty PLC | 0.50 | 0.02 | 0.48 |
| Barry Callebaut AG | 0.73 | 0.02 | 0.76 |
| Rumo SA | 0.42 | 0.03 | 0.41 |
| XP Power Ltd | 0.14 | 0.03 | 0.00 |
| Real Matters Inc | 0.23 | 0.03 | 0.27 |
| CyberArk Software Ltd | 0.83 | 0.03 | 0.90 |
| Fujitec Co Ltd | 1.16 | 0.03 | 1.18 |
| Daikokutenbussan Co Ltd | 0.85 | 0.04 | 1.02 |
| BasWare Oyj | 0.40 | 0.04 | 0.39 |

Source: Artisan Partners/FactSet. Performance is historical and is not a reliable indicator of future results. As of 30 Jun 2021. These investments made the greatest contribution to, or detracted most from, performance during the period based on a representative account within the strategy Composite. Upon request, Artisan will provide: (i) the calculation methodology and/or (ii) a list showing the contribution of each holding to overall performance during the measurement period. Securities of the same issuer are aggregated to determine the weight in the portfolio. % Contribution to Return is calculated by FactSet by multiplying a security's weight in the portfolio by its in portfolio return for the period referenced and does not take into account expenses of the portfolio. Purchases/sales are accounted for by using end of the day prices, which may or may not reflect the actual purchase/sale price realized by the portfolio.